KARDIOLOGIYA is a renowned academic journal in the field of cardiology, published by the Russian Heart Failure Society. Since its inception in 1961, this journal has been dedicated to disseminating cutting-edge research in cardiovascular medicine, contributing to the global understanding of heart-related diseases and their management. With a significant publication history that spans over six decades, KARDIOLOGIYA provides a platform for both established researchers and emerging scholars to publish their findings. Despite its current Q4 category ranking in the 2023 Cardiology and Cardiovascular Medicine category, the journal plays a crucial role in promoting regional insights and advancements in cardiology, while striving towards higher visibility and impact within the academic community. While not an open-access journal, the journal is accessible to institutions and professionals in the Russian Federation and beyond, fostering collaboration and knowledge sharing among healthcare professionals. With a Scopus rank of #259 among 387 journals, it is well-positioned to enhance discourse in the field and support the development of innovative approaches to cardiovascular care.

Kardiologia Polska, the esteemed journal of the Polish Cardiac Society, has established itself as a vital resource in the field of cardiology and cardiovascular medicine since its inception in 1954. With an ISSN of 0022-9032 and an E-ISSN of 1897-4279, this journal serves as a platform for groundbreaking research and scholarly articles that contribute to the advancement of heart health. Although currently not an open access journal, it remains an essential reference for practitioners and researchers seeking to stay abreast of the latest developments in cardiovascular science. The journal reflects its scholarly depth through a Category Quartile of Q3 and a commendable Scopus ranking at the 48th percentile in its field. Published primarily in Poland, it caters to a global audience eager to explore comprehensive studies spanning clinical cardiology, innovative therapeutic approaches, and emerging cardiovascular trends. Join a thriving academic community by engaging with the invaluable insights and research contributions found within the pages of Kardiologia Polska.

Expert Review of Anticancer Therapy, published by Taylor & Francis Ltd, is a distinguished journal focusing on the dynamic and ever-evolving field of oncology and pharmacology. Since its inception in 2001, this journal has played a pivotal role in disseminating critical reviews and analyses of novel anticancer therapies, fostering a deeper understanding among researchers and practitioners alike. With an impressive categorization in the 2023 Q2 quartiles for both Oncology and Pharmacology, it ranks #98 out of 272 in Pharmacology and #165 out of 404 in Oncology according to Scopus metrics, placing it well within the upper echelons of academic journals. The journal’s rigorous peer-review process ensures high-quality publications that are integral for advancing cancer research and therapeutic strategies. Although currently not an open access journal, it aims to bridge the gap between scientific discovery and clinical application, making it an essential resource for anyone involved in the fight against cancer.

JACC: CardioOncology, published by Elsevier, is a pioneering open-access journal that has been at the forefront of the intersection between cardiology and oncology since its inception in 2019. With a focus on innovative research aimed at understanding the cardiovascular implications of cancer therapies, it has swiftly achieved recognition, holding a prestigious Q1 category ranking in both Cardiology and Cardiovascular Medicine and Oncology as of 2023. The journal's high impact factor and notable Scopus rankings—20th out of 387 in Cardiology and 44th out of 404 in Oncology—underscore its essential role in disseminating cutting-edge findings that inform clinical practices and improve patient outcomes. JACC: CardioOncology aims to provide a comprehensive platform for researchers, healthcare professionals, and students to share and access vital information, facilitating collaborations that advance knowledge in this critical field. With its commitment to open access, the journal ensures that groundbreaking research is readily available to a global audience, fostering an inclusive environment for academia and practice alike.

International Heart Journal, published by INT HEART JOURNAL ASSOC, serves as a pivotal platform for research and discourse in the fields of cardiology and cardiovascular medicine. With its ISSN 1349-2365 and E-ISSN 1349-3299, this esteemed journal is based in Japan and is located at the University of Tokyo, Graduate School of Medicine, Department of Cardiovascular Medicine. Since its inception in 2005, International Heart Journal has blossomed into a respected publication with an impact factor that signifies its growing relevance, ranking in the Q3 category of both cardiology and miscellaneous medicine as of 2023. This journal not only disseminates vital research findings but also fosters collaboration among researchers and healthcare professionals. Notable for its Open Access options, it ensures the availability of its content to a broader audience, thereby enhancing knowledge transfer and innovation in cardiovascular care. With an ongoing commitment to improve clinical practice and patient outcomes, the journal continues to be an essential resource for those dedicated to advancing the understanding of heart health and disease.

Journal of Cardiovascular and Thoracic Research is a premier open access journal published by Tabriz University of Medical Sciences & Health Services, focusing on the dynamic fields of cardiology and cardiovascular medicine. With an ISSN of 2008-5117 and E-ISSN 2008-6830, the journal provides a platform for innovative research and advances in cardiovascular and thoracic health, catering to a global audience of researchers, healthcare professionals, and students. Since its inception as an open access publication in 2010, the journal has established itself within the academic community, evidenced by its inclusion in Scopus and its category quartile ranking (Q3) in 2023. Located in Tabriz, Iran, the journal aims to disseminate high-quality studies that contribute to the understanding and treatment of cardiovascular diseases, thus enabling advancements in this critical field of medicine. With a Scopus rank of 248 out of 387 in the category of Cardiology and Cardiovascular Medicine, the Journal of Cardiovascular and Thoracic Research is dedicated to fostering collaboration and dialogue among researchers and practitioners, promoting a deeper understanding of cardiovascular and thoracic health.

Heart Views is a prestigious and influential journal dedicated to the field of cardiology and cardiovascular medicine, published by Wolters Kluwer Medknow Publications. With an Open Access model implemented since 2010, the journal ensures that its valuable research findings are accessible to a global audience, fostering knowledge dissemination and collaboration among researchers, professionals, and students alike. While the current impact factor is not specified, its commitment to quality and peer-reviewed content has established it as a significant resource within the cardiology community. The journal publishes a diverse array of articles, including original research, reviews, and clinical studies aimed at advancing the understanding and treatment of cardiovascular diseases. Heart Views serves as an essential platform for sharing innovative ideas and practices, thereby contributing to improved patient care and outcomes in the dynamic field of heart health.

Medical Oncology, published by Humana Press Inc, stands as a significant contributor to the field of oncology, with its long-standing commitment to disseminating research and clinical findings relevant to the treatment and management of cancer. Established in 1994 and continuing through 2024, this journal publishes insightful articles that reflect the latest advancements in cancer research, hematology, and related medical fields. With an evolving impact factor and remarkable categorizations, including Q3 in Cancer Research and Q2 in both Hematology and Oncology, Medical Oncology serves as a pivotal resource for healthcare providers, researchers, and students dedicated to improving cancer outcomes. Although it does not offer open access, the journal is widely recognized for its rigorous peer-review process and high-quality publications, making it an essential platform for sharing innovative research and critical reviews in oncology.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, published by Elsevier Science Inc, stands at the forefront of the medical literature dedicated to advancing our understanding of cancer and blood disorders. With its ISSN 1040-8428 and E-ISSN 1879-0461, this prestigious journal boasts an impressive impact factor, reflecting its significance in the fields of Geriatrics, Hematology, and Oncology. Notably, it has achieved the distinction of being ranked in the top quartile (Q1) for these categories as of 2023, with Scopus rankings placing it in the 93rd percentile in Geriatrics and Gerontology, 87th in Oncology, and 85th in Hematology. Since its inception in 1983 and continuing until 2024, the journal serves as a critical resource for researchers, medical professionals, and students alike, aiming to publish high-quality, peer-reviewed articles that facilitate knowledge exchange and promote innovation in clinical practices and therapeutic strategies. While the journal is not open access, it remains widely accessible through various academic institutions, ensuring that vital research findings reach those who need them most.

Rational Pharmacotherapy in Cardiology, published by the SOC CARDIOLOGY RUSSIAN FEDERATION, stands as a crucial platform for advancing knowledge in the field of cardiology and pharmacology. Established as an Open Access journal in 2005, it allows for unrestricted access to research findings, fostering collaboration among researchers, clinicians, and students. The journal, with its ISSN 1819-6446 and E-ISSN 2225-3653, focuses on the intersection of rational pharmacotherapy and cardiovascular medicine, aiming to enhance treatment strategies and patient outcomes through evidence-based studies. Though currently positioned in the Q4 category in both cardiology and pharmacology rankings, its ongoing commitment to rigorous peer review and scholarly research ensures its relevance and growth in the scientific community. With a unique address in Moscow, Russia, the journal seeks to serve as a valuable resource for those dedicated to improving cardiovascular health and therapeutic practices worldwide, making it an essential read for professionals keen on the latest trends and discoveries in this vital area of medicine.